Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | FABP3 | P05413 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | PRKCG | P05129 | 1/20 | 0.35 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKCH | P24723 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25857265 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2FABP3LMNAAKT1ADRA1A | |
| SCHEMBL5959370 | 0.85 | FABP3 (0.48) | SMN1; SMN2FABP3LMNAAKT1ADRA1A | |
| SCHEMBL13212932 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2FABP3LMNAAKT1ADRA1A | |
| SCHEMBL10013706 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2FABP3LMNAAKT1ADRA1A | |
| SCHEMBL27168721 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2FABP3LMNAAKT1ADRA1A | |
| SCHEMBL157824 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2FABP3LMNAAKT1ADRA1A | |
| SCHEMBL101267 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2FABP3LMNAAKT1ADRA1A | |
| SCHEMBL5019714 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2FABP3LMNAAKT1ADRA1A | |
| SCHEMBL28015556 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2FABP3LMNAAKT1ADRA1A | |
| SCHEMBL14031370 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2FABP3LMNAAKT1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551332-B2 | Affinity particle and affinity separation method | SHISEIDO COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8551332-B2 | Affinity particle and affinity separation method | SHISEIDO COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20100137133-A1 | Affinity Particle And Affinity Separation Method | SHISEIDO COMPANY, LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20090321357-A1 | Affinity Particle And Affinity Separation Method | SHISEIDO COMPANY, LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090321358-A1 | Affinity Particle And Method Of Affinity Separation | SHISEIDO COMPANY, LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20070181503-A1 | Affinity particle and affinity separation method | SHISEIDO COMPANY, LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090321357-A1 | Affinity Particle And Affinity Separation Method | FCGR1A, ACP1, FCGR3B | SMN1; SMN2 4013/4885FABP3 312/4885LMNA 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.